Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2011-06-30 Share Issue/Capital Cha…
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
Vitrolifes aktiekapital och antal aktier per den 30 juni 2011
Share Issue/Capital Change Classification · 98% confidence The document is explicitly titled "Pressmeddelande" (Press Release) and announces the total number of outstanding shares and share capital as of a specific date (June 30, 2011). It details a change in the number of shares due to the exercise of stock options. This type of announcement, dealing with changes in the number of shares outstanding, directly relates to the company's capital structure. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate category for announcements regarding capital structure changes, even though it is a press release format. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a formal share issue report (SHA) which usually implies a larger offering or formal change filing, but rather a periodic update on the share count resulting from option exercises.
2011-06-30 Swedish
Vitrolife’s share capital and number of shares on June 30, 2011
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated June 30, 2011, detailing the change in the total number of shares and share capital as of that date. It explicitly mentions an increase in shares due to the exercising of options under a warrants program. This type of announcement, which reports a change in the number of outstanding shares or capital structure, directly corresponds to the 'Share Issue/Capital Change' definition. Therefore, the appropriate filing code is SHA.
2011-06-30 English
Klinisk studie med goda resultat vid användande av STEEN Solution™ publicerad i prestigefull vetenskaplig publikation
Regulatory Filings Classification · 95% confidence The document is a press release dated June 9, 2011, announcing positive clinical study results for the STEEN Solution™ published in the New England Journal of Medicine. It details medical/scientific findings and company updates related to transplantation technology. This type of announcement, which communicates significant operational or scientific news outside of mandatory periodic financial reports (like 10-K or IR), typically falls under general regulatory announcements or news releases. Since there is no specific category for 'Scientific/Clinical News Release' and it is not a standard financial filing (10-K, IR, ER), it best fits the 'Regulatory Filings' (RNS) category, which serves as a broad category for miscellaneous regulatory announcements. The document length (4050 chars) is substantial enough that it is the primary content, not just an announcement of a report (ruling 2 does not apply).
2011-06-09 Swedish
Clinical study with good results using STEEN Solution™ published in prestigious scientific journal
Regulatory Filings Classification · 95% confidence The document is a press release dated June 9, 2011, announcing positive clinical study results for a medical product (STEEN Solution™) published in the New England Journal of Medicine. It discusses clinical outcomes, mentions specific hospitals, and includes contact information for the CEO and CFO. This format—a short, timely announcement of significant operational or clinical news, often referencing external publications or events—is characteristic of a general press release or regulatory announcement that doesn't fit the specific financial report categories (10-K, IR, ER, etc.). Since it is an announcement of clinical/scientific progress rather than a formal financial filing, and it doesn't fit other specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory/public announcements.
2011-06-09 English
Vitrolife får som första företag i Kina regulatoriskt godkännande för en hel serie av odlingsmedier för IVF.
Regulatory Filings Classification · 95% confidence The document is titled "Pressmeddelande" (Press Release) dated May 5, 2011, announcing a specific corporate event: receiving regulatory approval in China for a series of IVF culture media. This is a material, non-financial announcement intended for the public and investors. It is not a formal statutory filing like a 10-K, an earnings release (ER), or a detailed financial report (IR). Since it is a general, timely announcement of a significant business development (regulatory approval), it fits best under the general category for regulatory/corporate announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is too specific for RNS if a better fit existed, but among the options, RNS serves as the best catch-all for press releases detailing operational milestones.
2011-05-05 Swedish
Vitrolife is the first company in China to receive regulatory approval for an entire IVF culture media portfolio.
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Press Release" dated May 5, 2011, announcing a specific corporate event: receiving regulatory approval from the Chinese SFDA for an IVF culture media portfolio. This is not a comprehensive financial report (like 10-K or IR), nor is it a transcript, dividend notice, or management change announcement. It is a specific, time-sensitive announcement regarding regulatory status and market access, which often falls under general regulatory news or a specific regulatory filing announcement. Since it is a press release announcing a regulatory achievement (SFDA approval), and there is no specific category for 'Regulatory Approval Announcement', it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory news that isn't a formal SEC/exchange filing like a 10-K or a specific transaction report. Given the content is about regulatory compliance and market access, RNS is the most appropriate fit among the provided options.
2011-05-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.